< 1 minute read
Dec. 20, 2021
PF-06939999 is a SAM-Competitive PRMT5 Inhibitor
PF-06939999
oral SAM-competitive PRMT5 inhibitor Ph. I candidate for solid tumors (adv. or met.) SBDD utilizing PRMT5:MEP50 w/ A9145C Molecular Cancer Therapy Pfizer Oncology
Loading...
